Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$65.13 +18.2%	$44.67	$30.04 ▼ $66.10	$4.76B	1.82	1.99 million shs	10.16 million shs
NTLA Intellia Therapeutics	$12.06 +1.9%	$9.46	$5.90 ▼ $27.42	$1.23B	2.21	3.07 million shs	3.83 million shs
REGN Regeneron Pharmaceuticals	$542.52 -1.4%	$544.14	$476.49 ▼ $1,211.20	$59.38B	0.33	927,895 shs	1.31 million shs
VRTX Vertex Pharmaceuticals	$459.81 -0.7%	$448.80	$377.85 ▼ $519.88	$118.97B	0.41	1.42 million shs	975,143 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	-0.09%	-6.63%	+27.55%	+45.86%	-8.91%
NTLA Intellia Therapeutics	-1.09%	-2.71%	+23.49%	+63.62%	-56.76%
REGN Regeneron Pharmaceuticals	+0.38%	-1.74%	+8.08%	-2.34%	-49.34%
VRTX Vertex Pharmaceuticals	-1.34%	-3.39%	+4.81%	-5.28%	-5.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRSP CRISPR Therapeutics	2.69 of 5 stars	3.3	1.0	0.0	0.0	3.3	3.3	0.6
NTLA Intellia Therapeutics	4.4128 of 5 stars	4.3	1.0	0.0	4.7	1.9	2.5	0.6
REGN Regeneron Pharmaceuticals	4.777 of 5 stars	4.4	3.0	1.7	2.3	2.1	1.7	1.9
VRTX Vertex Pharmaceuticals	4.7262 of 5 stars	3.3	5.0	0.0	3.3	4.0	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRSP CRISPR Therapeutics	2.53	Moderate Buy	$71.75	10.16% Upside
NTLA Intellia Therapeutics	2.65	Moderate Buy	$33.37	176.69% Upside
REGN Regeneron Pharmaceuticals	2.80	Moderate Buy	$814.57	50.14% Upside
VRTX Vertex Pharmaceuticals	2.54	Moderate Buy	$511.71	11.29% Upside

Current Analyst Ratings Breakdown

Latest CRSP, VRTX, NTLA, and REGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	VRTX Vertex Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$515.00 ➝ $517.00
7/11/2025	REGN Regeneron Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$560.00 ➝ $584.00
7/10/2025	REGN Regeneron Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$755.00 ➝ $754.00
7/8/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/30/2025	REGN Regeneron Pharmaceuticals	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
6/27/2025	CRSP CRISPR Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$105.00
6/27/2025	CRSP CRISPR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00
6/27/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00
6/26/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/26/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
6/23/2025	VRTX Vertex Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$550.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRSP CRISPR Therapeutics	$37.31M	150.75	N/A	N/A	$22.64 per share	2.88
NTLA Intellia Therapeutics	$57.88M	21.58	N/A	N/A	$8.56 per share	1.41
REGN Regeneron Pharmaceuticals	$14.20B	4.12	$45.10 per share	12.03	$268.50 per share	2.02
VRTX Vertex Pharmaceuticals	$11.02B	10.71	N/A	N/A	$63.72 per share	7.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRSP CRISPR Therapeutics	-$366.25M	-$4.52	N/A	N/A	N/A	-1,023.64%	-20.08%	-17.13%	8/4/2025 (Estimated)
NTLA Intellia Therapeutics	-$519.02M	-$5.23	0.00	N/A	N/A	-1,154.10%	-56.06%	-44.25%	8/14/2025 (Estimated)
REGN Regeneron Pharmaceuticals	$4.41B	$39.28	14.41	14.27	2.04	31.94%	15.27%	11.93%	8/1/2025 (Estimated)
VRTX Vertex Pharmaceuticals	-$535.60M	-$3.92	0.00	26.26	N/A	-8.91%	-3.36%	-2.42%	8/4/2025 (Confirmed)

Latest CRSP, VRTX, NTLA, and REGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	NTLA Intellia Therapeutics	-$1.03	N/A	N/A	N/A	$12.26 million	N/A
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.54	N/A	N/A	N/A	$6.44 million	N/A
8/4/2025	Q2 2025	VRTX Vertex Pharmaceuticals	$4.24	N/A	N/A	N/A	$2.90 billion	N/A
8/1/2025	Q2 2025	REGN Regeneron Pharmaceuticals	$8.53	N/A	N/A	N/A	$3.30 billion	N/A
5/8/2025	Q1 2025	NTLA Intellia Therapeutics	-$1.26	-$1.10	+$0.16	-$1.10	$11.39 million	$16.63 million
5/6/2025	Q1 2025	CRSP CRISPR Therapeutics	-$1.27	-$1.58	-$0.31	-$1.58	N/A	N/A
5/5/2025	Q1 2025	VRTX Vertex Pharmaceuticals	$4.29	$4.06	-$0.23	$2.49	$2.85 billion	$2.77 billion
4/29/2025	Q1 2025	REGN Regeneron Pharmaceuticals	$8.83	$8.22	-$0.61	$7.27	$3.40 billion	$3.03 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.52	0.65%	N/A	8.96%	N/A
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest CRSP, VRTX, NTLA, and REGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.6%	5/20/2025	5/20/2025	6/6/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRSP CRISPR Therapeutics	N/A	15.64	15.64
NTLA Intellia Therapeutics	N/A	4.90	4.90
REGN Regeneron Pharmaceuticals	0.09	4.93	4.03
VRTX Vertex Pharmaceuticals	0.01	2.65	2.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRSP CRISPR Therapeutics	69.20%
NTLA Intellia Therapeutics	88.77%
REGN Regeneron Pharmaceuticals	83.31%
VRTX Vertex Pharmaceuticals	90.96%

Insider Ownership

Company	Insider Ownership
CRSP CRISPR Therapeutics	4.30%
NTLA Intellia Therapeutics	3.10%
REGN Regeneron Pharmaceuticals	7.02%
VRTX Vertex Pharmaceuticals	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRSP CRISPR Therapeutics	460	86.36 million	82.65 million	Optionable
NTLA Intellia Therapeutics	600	103.58 million	100.37 million	Optionable
REGN Regeneron Pharmaceuticals	15,106	107.96 million	100.39 million	Optionable
VRTX Vertex Pharmaceuticals	6,100	256.80 million	256.28 million	Optionable

CRSP, VRTX, NTLA, and REGN Headlines

Recent News About These Companies

Mystic Asset Management Inc. Invests $970,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

July 18 at 11:36 AM | marketbeat.com

Nwam LLC Sells 1,436 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

July 18 at 11:12 AM | marketbeat.com

Diversify Advisory Services LLC Purchases 827 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

July 18 at 11:09 AM | marketbeat.com

C WorldWide Group Holding A S Cuts Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

July 18 at 10:27 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Position Raised by Jennison Associates LLC

July 18 at 9:29 AM | marketbeat.com

Cwm LLC Boosts Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

July 18 at 4:42 AM | marketbeat.com

2,000 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bought by Retirement Planning Co of New England Inc.

July 17 at 9:41 AM | marketbeat.com

Victory Capital Management Inc. Sells 11,261 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

July 17 at 6:51 AM | marketbeat.com

What is William Blair's Forecast for VRTX FY2025 Earnings?

July 17 at 3:31 AM | americanbankingnews.com

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It

July 16 at 10:01 AM | zacks.com

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

July 16 at 9:51 AM | zacks.com

Triasima Portfolio Management inc. Reduces Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

July 16 at 8:59 AM | marketbeat.com

Welch & Forbes LLC Boosts Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

July 16 at 8:44 AM | marketbeat.com

Grandfield & Dodd LLC Raises Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

July 16 at 8:34 AM | marketbeat.com

Segall Bryant & Hamill LLC Has $25.61 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

July 16 at 7:54 AM | marketbeat.com

Bridgewater Advisors Inc. Purchases Shares of 1,113 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

July 16 at 7:09 AM | marketbeat.com

William Blair Has Negative Outlook for VRTX FY2025 Earnings

July 16 at 6:46 AM | marketbeat.com

PAX Financial Group LLC Takes $316,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

July 16 at 6:44 AM | marketbeat.com

Vertex Pharmaceuticals: Strong Growth Driven by Cystic Fibrosis Success and Strategic Expansions

July 16 at 6:24 AM | tipranks.com

Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $517.00

July 16 at 3:01 AM | americanbankingnews.com

Equities Analysts Offer Predictions for VRTX Q2 Earnings

July 16 at 2:21 AM | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook
By Brian O'Connell | July 15, 2025
View Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook

CRSP, VRTX, NTLA, and REGN Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

$65.13 +10.04 (+18.22%)

Closing price 04:00 PM Eastern

Extended Trading

$64.90 -0.23 (-0.35%)

As of 07:59 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Intellia Therapeutics NASDAQ:NTLA

$12.06 +0.23 (+1.94%)

Closing price 04:00 PM Eastern

Extended Trading

$12.04 -0.02 (-0.12%)

As of 07:59 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Regeneron Pharmaceuticals NASDAQ:REGN

$542.52 -7.48 (-1.36%)

Closing price 04:00 PM Eastern

Extended Trading

$545.00 +2.49 (+0.46%)

As of 07:54 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Vertex Pharmaceuticals NASDAQ:VRTX

$459.81 -3.46 (-0.75%)

Closing price 04:00 PM Eastern

Extended Trading

$464.10 +4.30 (+0.93%)

As of 07:22 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time